Gene expression–based molecular predictor for major PTCL entities. Amador et al¹⁰⁷ used gene expression profiling for major PTCL subsets to differentiate each PTCL subtype including the novel molecular subtypes (PTCL-GATA3 and PTCL-TBX21). Shown are the expressions of known distinct transcripts for each patient in a molecular PTCL subtype (the detailed characteristics of these transcripts have been described in Amador et al¹⁰⁷). Key histopathological features and immunohistochemistry biomarkers for each PTCL entity are shown under each molecular subtype.